



[CLICK TO VIEW](#)

[Table of Contents 2](#)

[List of Tables & Charts 3](#)

[Study Overview 4](#)

[Sample Text, Table & Chart 5](#)

[Sample Profile, Table & Forecast 6](#)

[Order Form & Corporate Use License 7](#)

[About Freedonia, Custom Research, Related Studies, 8](#)

# Drug Delivery Products

---

US Industry Study with Forecasts for **2015 & 2020**

---

Study #2829 | January 2012 | \$4800 | 337 pages

---

[www.freedoniagroup.com](http://www.freedoniagroup.com)



**The Freedonia Group**

767 Beta Drive

Cleveland, OH • 44143-2326 • USA

Toll Free US Tel: 800.927.5900 or +1 440.684.9600

Fax: +1 440.646.0484

E-mail: [info@freedoniagroup.com](mailto:info@freedoniagroup.com)

## Table of Contents

### EXECUTIVE SUMMARY

### MARKET ENVIRONMENT

General .....	4
Economic Factors .....	5
Demographic Patterns .....	8
Health Care Trends .....	11
Health Insurance .....	12
Medical Conditions .....	14
Acute Conditions .....	15
Chronic Conditions .....	16
National Health Expenditures .....	19
Medical Providers .....	22
Hospitals .....	23
Skilled Nursing Homes .....	23
Outpatient Facilities .....	23
Physicians .....	24
Patient Activity .....	24
Hospital Activity .....	26
Surgical Procedures .....	26
Outpatient Consultations .....	26
Pharmaceutical Market Overview .....	28
Regulation .....	29
Research & Development .....	30
Demand Patterns .....	32
Therapeutic Classes .....	32
Dosage Formulations .....	34
Distribution Classification .....	37
Commercial Status .....	38

### DRUG DELIVERY EXCIPIENTS

General .....	42
Polymers .....	43
Polyethylene Glycol .....	44
Acrylic Polymers .....	46
Carbomers .....	46
Methacrylate Copolymers .....	47
Polyethylene Oxide .....	48
Polyvinyl Alcohol .....	49
Other Synthetic Polymers .....	49
Cellulose Excipients .....	50
Ethyl Cellulose .....	51
Hydroxypropyl Methylcellulose (HPMC) .....	52
Other Cellulose Excipients .....	53
Minerals .....	54
Mineral Hydrocarbons .....	55
Petrolatum .....	55
Mineral Oil .....	56
Waxes .....	57
Other Minerals .....	57
Attapulgate .....	57
Calcium Carbonate .....	58
Calcium Silicate .....	59
Electrolytes .....	59
Other Excipients .....	59
Sterile & Purified Waters .....	60

Starch Compounds .....	62
Cyclodextrins .....	62
Dextrates .....	62
Dextrin .....	63
Maltodextrin .....	63
Sugars & Polyols .....	63
Sucrose .....	63
Sorbitol .....	64
Lactose .....	65
Mannitol .....	65
Natural Gums .....	66
All Other Excipients .....	66

### DRUG DELIVERY PRODUCTS OVERVIEW

General .....	68
Types of Drug Delivery Products .....	70
Historical Market Trends .....	72
Regulation .....	75
Research & Development .....	76
US Trade .....	77
International Markets .....	78

### ORAL DRUG DELIVERY PRODUCTS

General .....	81
Controlled-Release Formulations .....	83
Coated Products .....	86
Diffusion Products .....	89
Reservoir Products .....	91
Chewable Tablets .....	93
Nanoparticulate Formulations .....	96
Orally Disintegrating Tablets (ODT) .....	99
Transmucosal Formulations .....	101

### PARENTERAL DRUG DELIVERY PRODUCTS

General .....	105
Therapeutic Monoclonal Antibodies .....	107
Types of Monoclonal Antibodies .....	109
Marketed Products .....	111
Therapeutic Monoclonal Antibodies in Development .....	130
Encapsulated Parenteral Drug Delivery Products .....	135
Polymer-Protected Products .....	136
PEG-Based Parenteral Therapies .....	137
Other Polymer-Protected Parenteral Therapies .....	140
Developmental Activities .....	141
Liposomes .....	143
Marketed Products .....	144
Developmental Activities .....	145
Infusion Products .....	146
IV Administration Sets .....	147
Premixed IV Solutions .....	149

Infusion Pumps .....	150
Other Infusion Products .....	152
Enteral Feeding Supplies .....	152
IV Accessories .....	153
Parenteral Drug Delivery Devices .....	154
Prefillable Syringes .....	155
Injectors .....	155
Cartridges .....	157
Hypodermic Syringes .....	160
IV Catheters .....	161
Other Parenteral Delivery Devices .....	163

### OTHER DRUG DELIVERY PRODUCTS

General .....	165
Inhalation Drug Delivery Products .....	167
Dry Powder Formulations .....	168
Types of DPIs .....	170
Developmental Activities .....	171
Metered Dose Formulations .....	172
3M Drug Delivery Systems .....	173
Other Producers .....	174
Implantable Drug Delivery Products .....	176
Drug-Eluting Stents .....	177
Other Implantable Drug Delivery Products .....	181
Drug Inserts .....	182
Brachytherapy .....	183
Drug Pumps .....	186
Transdermal Drug Delivery Products .....	187
Transdermal Technologies .....	189
Central Nervous System Agents .....	190
Other Transdermal Therapies .....	193
Hormones & Related Agents .....	193
OXYTROL .....	195
Cardiovascular Agents .....	195
Nicotine Patches .....	196
Scopolamine .....	197

### APPLICATIONS

General .....	198
Central Nervous System Agents .....	200
Respiratory Agents .....	203
Hormones & Related Agents .....	206
Gastrointestinal Agents .....	211
Cardiovascular Agents .....	213
Anti-Infective Agents .....	217
Nutritional Agents .....	219
Genito-Urinary Agents .....	221
Other Pharmaceuticals .....	223

### INDUSTRY STRUCTURE

General .....	227
Market Share .....	230
Competitive Strategies .....	232
Mergers & Acquisitions .....	234
Licensing & Related Agreements .....	238
Marketing & Distribution .....	244
Manufacturing .....	245

## Table of Contents

### COMPANY PROFILES

(continued from previous page)

Abbott Laboratories.....	248
Amgen Incorporated.....	251
Aptalis Pharma.....	254
AptarGroup Incorporated.....	258
AstraZeneca plc.....	261
Baxter International.....	265
Becton, Dickinson and Company.....	268
Boehringer Ingelheim.....	273
Boston Scientific.....	276
Braun (B.) Melsungen.....	277
Bristol-Myers Squibb.....	280
Evonik Industries.....	283
GlaxoSmithKline plc.....	286
Hospira Incorporated.....	290
Johnson & Johnson.....	295
Lilly (Eli) and Company.....	300
Merck & Company.....	303
Nitto Denko.....	307
Novartis AG.....	310
Novo Nordisk.....	314
Pfizer Incorporated.....	316
Roche Holding.....	318
Sanofi-Aventis.....	322
Teva Pharmaceutical Industries.....	326
3M Company.....	329
Unilife Corporation.....	332
West Pharmaceutical Services.....	335

## List of Tables/Charts

### EXECUTIVE SUMMARY

1 Summary Table.....	3
----------------------	---

### MARKET ENVIRONMENT

1 Macroeconomic Indicators.....	8
2 Population by Age Group.....	11
3 Health Insurance Coverage of the US Population.....	14
4 Acute Conditions by Type.....	16
5 Chronic Conditions by Type.....	19
6 National Health Expenditures by Type.....	21
7 Medical Providers by Type.....	22
8 Patient Activity by Type & Volume.....	25
9 Pharmaceutical Demand by Therapeutic Class.....	34
10 Pharmaceutical Demand by Dosage Formulation.....	36
11 Pharmaceutical Demand by Distribution Classification.....	38
12 Pharmaceutical Demand by Commercial Status.....	39

### DRUG DELIVERY EXCIPIENTS

1 Drug Delivery Excipient Demand by Product Group.....	43
2 Polymer Drug Delivery Excipient Demand by Type.....	44
3 Cellulose Drug Delivery Excipient Demand by Type.....	51
4 Mineral Drug Delivery Excipient Demand by Type.....	55
5 Other Drug Delivery Excipient Demand by Type.....	60

### DRUG DELIVERY

#### PRODUCTS OVERVIEW

1 Drug Delivery Product Demand by Dosage Formulation.....	69
Cht Drug Delivery Product Demand by Dosage Formulation, 2010.....	70
2 Drug Delivery Product Demand, 2000-2010.....	75
3 US Trade in Drug Delivery Products.....	78
4 World Drug Delivery Product Demand by Region.....	80

### ORAL DRUG

#### DELIVERY PRODUCTS

1 Oral Drug Delivery Product Demand by Type.....	82
Cht Oral Drug Delivery Product Demand by Type, 2010.....	83
2 Oral Controlled-Release Drug Delivery Product Demand by Type, Mode of Action & Application.....	85
Cht Oral Controlled-Release Drug Delivery Product Demand by Type, 2010.....	86
3 Oral Coated Drug Delivery Product Demand.....	89
4 Oral Diffusion Drug Delivery Product Demand.....	91
5 Oral Reservoir Drug Delivery Product Demand.....	93
6 Chewable Tablet Demand by Therapeutic Class.....	95
7 Oral Nanoparticulate Product Demand by Application.....	98
8 Orally Disintegrating Tablet (ODT) Demand by Application.....	101
9 Transmucosal Product Demand.....	104

### PARENTERAL DRUG

#### DELIVERY PRODUCTS

1 Parenteral Drug Delivery Product Demand by Type.....	106
Cht Parenteral Drug Delivery Product Demand by Type, 2010.....	107
2 Therapeutic Monoclonal Antibody Demand by Application.....	109

3 Therapeutic Monoclonal Antibodies Approved for US Sale.....	113
4 Encapsulated Parenteral Product Demand by Type & Application.....	136
5 Infusion Product Demand by Type.....	147
6 Parenteral Delivery Device Demand by Type.....	154

### OTHER DRUG

#### DELIVERY PRODUCTS

1 Other Drug Delivery Product Demand by Type.....	166
Cht Other Drug Delivery Product Demand by Type, 2010.....	167
2 Inhalation Drug Delivery Product Demand by Type.....	168
3 Dry Powder Inhaler Product Demand.....	170
4 Metered Dose Inhaler (MDI) Product Demand.....	173
5 Implantable Drug Delivery Product Demand by Type & Application.....	177
6 Drug-Eluting Stent Demand.....	180
7 Other Implantable Drug Delivery Product Demand by Type.....	181
8 Transdermal Product Demand by Application.....	189

### APPLICATIONS

1 Drug Delivery Product Demand by Application.....	199
Cht Drug Delivery Product Demand by Application, 2010.....	200
2 Central Nervous System (CNS) Drug Delivery Product Demand by Type.....	203
3 Respiratory Drug Delivery Product Demand by Type.....	206
4 Hormone & Related Drug Delivery Product Demand by Type.....	211
5 Gastrointestinal Drug Delivery Product Demand by Type.....	213
6 Cardiovascular Drug Delivery Product Demand by Type.....	217
7 Anti-Infective Drug Delivery Product Demand by Type.....	219
8 Nutritional Drug Delivery Product Demand by Type.....	221
9 Genito-Urinary Drug Delivery Product Demand by Type.....	223
10 Drug Delivery Product Demand in Other Pharmaceuticals by Type.....	226

### INDUSTRY STRUCTURE

1 US Drug Delivery Product Sales by Company, 2010.....	228
Cht Drug Delivery Dosage Formulations, US Market Share, 2010.....	231
Cht Drug Delivery Devices, US Market Share, 2010.....	232
2 Selected Acquisitions & Divestitures.....	236
3 Selected Cooperative Agreements.....	240

*The best growth opportunities will emerge in dosage formulations that improve therapy for autoimmune conditions, cancer, heart disease, neurological disorders and other debilitating illnesses.*

## US demand to rise 7.4% annually through 2015


US demand for drug delivery products will expand 7.4 percent annually to \$134 billion in 2015. The best growth opportunities will emerge in dosage formulations that advance the nature of therapy for autoimmune conditions, cancer, heart disease, neurological disorders and other debilitating health problems. Drug delivery devices with improved safety, infection prevention and ease-of-use features will also fare well in the marketplace. Based on the complex nature of therapy and the high frequency of dosing requirements, central nervous system and hormonal and related conditions will be the fastest growing indications served by drug delivery products.

## Parenteral drug delivery products to grow fastest

Demand for oral drug delivery products will increase 4.3 percent annually to over \$52 billion in 2015. Controlled-release formulations will command the largest share of sales, but will lose some growth momentum due to patent expirations on several large-selling sustained-release therapies. Nanoparticulate medicines will record some of the fastest growth among oral drug delivery products based on new products and the high value-added nature of indications served.

Demand for parenteral drug delivery products will reach \$54.7 billion in 2015, up nearly eleven percent annually from 2010. Monoclonal antibodies will lead

## US Drug Delivery Product Demand (\$134 billion, 2015)



gains as advances in biotechnology lead to the introduction of new and improved therapies for autoimmune disorders, cancer and various rare debilitating diseases. Polymer-encapsulated medicines will also record fast rising demand based on contributions to the improved bioavailability and reduced toxicity of advanced parenteral compounds. Safety-engineered prefillable syringes and IV catheters, along with bag/vial infusion systems, will post the best growth among parenteral delivery devices based largely on infection prevention advantages.

Demand for other drug delivery products will rise 7.4 percent annually to \$27.1 billion in 2010. Prefilled dry powder and metered dose inhalers will retain the

largest share of sales, spurred by upward trends in prevalence of asthma and chronic obstructive pulmonary disease (COPD). However, growth for these devices will decelerate as patent expirations open up several widely prescribed inhalation therapies, including sales leader ADVAIR (GlaxoSmithKline), to generic competition. Demand for implantable drug delivery products will increase nearly eleven percent annually through 2015 led by new brachytherapy offerings for cancer and macular degeneration. Additionally, the US market for drug-eluting stents will rebound from a recent downturn as next-generation devices with thinner struts and improved safety profiles promote expansion in the volume of angioplasty procedures.

Copyright 2012 The Freedonia Group, Inc.

[Click here to purchase online](#)



## Sample Text, Table & Chart

### PARENTERAL DRUG DELIVERY PRODUCTS

#### Prefillable Syringes

Prefillable syringes are projected to post demand of near billion in 2015, up from 2010. Increasing trends in the delivery of parenteral medicine and patient-acceptable parenteral medical products, and advances in biotechnology and other life sciences are driving a range of potentially adaptable to prefillable syringes.

**SAMPLE TEXT**

Prefillable syringes are the principal product. Prefilled cartridges adaptable to reusable pen-type injectors will account for the larger unit consumption based on application packaging of insulin and other medicines indicated for self-administration. However, disposable injectors will record the larger demand value due to their complexity of design and use in the of more sophisticated medicines.

**Injectors** -- Disposable injectors provide a unit dose, ready-to-use parenteral drug delivery device. The format enables medical professionals to offer drug therapy quickly in life-threatening and other emergency situations. Other major benefits involve the elimination of cross-contamination risks associated with standard hypodermic administration.

The design of standard prefilled syringe injectors incorporates a cylinder-shaped glass cartridge containing the parenteral solution in liquid form. A rubber plunger connected to a movable plastic component is affixed to one end of the cartridge with a hypodermic needle connected to a protective plastic or rubber shield attached to the opposite end. Types of standard prefilled syringe injectors vary in capacity from 0.5 to 50 milliliters.

Variations of the basic prefilled syringe injector design include a dual compartment device for the administration of powder for

155

Copyright 2012

TABLE VI-4


### ENCAPSULATED PARENTERAL PRODUCT DEMAND BY TYPE & APPLICATION (million dollars)

Item	2000	2005	2010	2015	2020
Chronic Conditions (million \$ encapsulated products/condition)					
Encapsulated Parenteral Product Demand					
By Type:					
Polymer-Protected Products					
Liposomes					
By Application:					
Hormones & Related Agents					
Central Nervous System Agents					
Anti-Infective Agents					
Other Classes					
% encapsulated products					
Parenteral Drug Delivery Prod Dmnd	6410	18520	32000	34700	84000

**SAMPLE TABLE**

CHART IX-1

### DRUG DELIVERY DOSAGE FORMULATIONS, US MARKET SHARE (\$85.1 billion, 2010)




**SAMPLE CHART**

## Sample Profile, Table & Forecast

**TABLE V-1**  
**ORAL DRUG DELIVERY PRODUCT DEMAND BY TYPE**  
 (million dollars)

Item	2000	2005	2010	2015	2020
Oral Pharmaceutical Demand (bil \$)					
\$ drug delivery products/000\$ phar					
Oral Drug Delivery Product Demand					
Controlled-Release					
Chewable					
Nanoparticulate					
Orally Disintegrating					
Transmucosal					
% oral					
Drug Delivery Product Demand					



### COMPANY PROFILES

**Aptalis Pharma Incorporated**  
 597 Laurier Boulevard  
 Mont-Saint-Hilaire, Quebec J3H 6C4  
 Canada  
 450-467-5138  
<http://www.ap>



Annual Sales:  
 Employment:

Key Technologies: ... technologies,  
 dosage formul... g delivery  
 platforms; and p... very systems

Aptalis Pharma, which changed its name from Axcan Intermediate Holdings Incorporated in May 2011, is a leading international specialty pharmaceutical company that develops, manufactures, markets and distributes cystic fibrosis and gastroenterology products and therapeutic treatments. The Company is privately held.

Aptalis Pharma entered the US drug delivery product industry in February 2011 when the Company, which operated as Axcan Intermediate Holdings at the time, purchased specialty pharmaceutical company Eurand NV (Netherlands). Eurand is involved in the development and licensing of proprietary drug formulation technologies in the areas of customized release platforms, dosage formulations and bioavailability enhancement. Specific technologies include DIFFUCAPS, DIFFUTAB, ORBEXA, ADVATAB, BIORISE, MICROCAPS, LIQUITARD and EURAND MINITABS. In addition, the company engages in the manufacture and commercialization of pharmaceutical and biopharmaceutical products based on these technologies. Following the transaction, Eurand's activities related to customized drug release technologies and

“Demand for oral controlled-release medication adapted to reservoir technology is projected to increase 3.2 percent annually to \$2.0 billion in 2015. Gains will reflect advantages of stable zero order drug release and long duration of action. The range of applications and extent of growth opportunities for reservoir drug delivery platforms will be limited by complex formulating requirements and high manufacturing costs. These disadvantages will ...”  
 --Section V, pg. 91

ONLINE: www.freedoniagroup.com

MAIL: Print out and complete the order form and send to The Freedonia Group (see address at the bottom of this form)

PHONE: Call toll free, 800.927.5900 (US) or + 1 440.684.9600

FAX: + 1 440.646.0484 (US)

EMAIL: info@freedoniagroup.com

Free Handling & Shipping

There is NO charge for handling or UPS shipping in the US. Expect delivery in 3 to 5 business days. Outside the US, Freedonia provides free airmail service. Express delivery is available at cost.

Orders Outside of the US

Checks must be made payable in US funds, drawn against a US bank and mailed directly to The Freedonia Group. For wire transfers please contact our customer service department at info@freedoniagroup.com. Credit cards accepted.

Credit Card Orders

For convenience, Freedonia accepts American Express, MasterCard or Visa. Credit card purchases must include account number, expiration date and authorized signature.

Save 15%

If you order three (3) different titles at the same time, you can receive a 15% discount. If your order is accompanied by a check or wire transfer, you may take a 5% cash discount (discounts do not apply to Corporate Use Licenses).

Corporate Use License

Now every decision maker in your organization can act on the key intelligence found in all Freedonia studies. For an additional \$2600, companies receive unlimited use of an electronic version (PDF) of the study. Place it on your intranet, e-mail it to coworkers around the world, or print it as many times as you like,

Click here to learn more about the Corporate Use License

ORDER FORM

F-WEB.-2829

Drug Delivery Products ..... \$4800

Corporate Use License (add to study price) \* + \$2600

Additional Print Copies @ \$600 each \*

Total (including selected option) \$\_\_\_\_\_

Enclosed is my check (5% discount) drawn on a US bank and payable to The Freedonia Group, Inc., in US funds (Ohio residents add 7.75% sales tax)

Bill my company American Express MasterCard Visa

Credit Card #

Expiration Date MM YY

Signature \_\_\_\_\_

Name \_\_\_\_\_

Title \_\_\_\_\_

Company \_\_\_\_\_

Division \_\_\_\_\_

Street (No PO Box please)

City/State/Zip \_\_\_\_\_

Country \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Email \_\_\_\_\_

\* Please check appropriate option and sign below to order an electronic version of the study.

Corporate Use License Agreement

The above captioned study may be stored on the company's intranet or shared directory, available to company employees. Copies of the study may be made, but the undersigned represents that distribution of the study will be limited to employees of the company.

Signature \_\_\_\_\_

Individual Use License Agreement

The undersigned hereby represents that the above captioned study will be used by only \_\_\_ individual(s) who are employees of the company and that the study will not be loaded on a network for multiple users. In the event that usage of the study changes, the Company will promptly notify Freedonia of such change and will pay to Freedonia the appropriate fee based on Freedonia's standard fee schedule then in effect. Note: Entire company corporate use license, add \$2600; one additional user, add \$600; two additional users, add \$1200; three additional users, add \$1800.

Signature \_\_\_\_\_

**OTHER STUDIES**

**World Home Medical Equipment**

World demand for home medical equipment will rise 7.0 percent yearly to \$28 billion in 2016. The US will remain the largest market while Brazil, China, India, and Russia will be among the fastest growing. Portable oxygen concentrators, remote patient monitors and home dialysis machines will offer some of the best opportunities. This study analyzes the \$20 billion world home medical equipment industry, with forecasts for 2016 and 2021 by product, world region and for 15 major countries. The study also evaluates company market share and profiles industry players.  
 #2964 .....January 2013 ..... \$6300

**In Vitro Diagnostics**

US demand for *in vitro* diagnostic (IVD) products will rise 6.1 percent annually to \$24.7 billion in 2016. Molecular diagnostic products will grow the fastest due to their advantages in the detection of infectious diseases, tumors and genetic disorders. Hospital labs will continue to comprise the largest and most diverse market. This study analyzes the \$18.4 billion US IVD products industry, with forecasts for 2016 and 2021 by type, application and market. The study also considers market environment factors, evaluates company market share and profiles industry players.  
 #2923 ..... July 2012 ..... \$5100

**Disposable Medical Supplies**

US disposable medical supplies demand will rise 4.3 percent yearly to \$46.7 billion in 2016. Syringes and inhalers, IV and urinary catheters, hemodialysis bloodlines, peritoneal dialysis kits, tissue sealants, biological wound dressings, Class IV garments and textiles, and blood glucose test strips will be among the fastest growing products. This study analyzes the \$37.8 billion US disposable medical supplies industry, with forecasts for 2016 and 2021 by product, market and material. The study also evaluates company market shares and profiles industry players.  
 #2853 ..... March 2012 ..... \$5100

**Implantable Medical Devices**

US demand for implantable medical devices is forecast to increase 7.7 percent annually to \$52 billion in 2015. Orthopedic implants will remain the largest segment and be one of the fastest growing. Pacing devices will lead gains among cardiovascular implants. Other implants expected to do well include neurostimulators and drug implants. This study analyzes the \$36 billion US implantable medical device industry, with forecasts for 2015 and 2020 by implant procedure, material and type. The study also evaluates company market share and profiles industry players.  
 #2852 ..... March 2012 ..... \$5100

**World Nutraceutical Ingredients**

World demand for nutraceutical ingredients will rise 7.2 percent annually to \$23.7 billion in 2015. Developing regions will achieve much faster growth in both consumption and production than developed regions. Naturally derived herbal and botanical extracts and marine-based derivatives will command the fastest growth. This study analyzes the \$16.8 billion world nutraceutical ingredient industry, with forecasts for 2015 and 2020 by product, world region and for 43 countries. The study also evaluates company market share and profiles industry players.  
 #2799 ..... November 2011 ..... \$6100

**About The Freedonia Group**

The Freedonia Group, Inc., is a leading international industry market research company that provides its clients with information and analysis needed to make informed strategic decisions for their businesses. Studies help clients identify business opportunities, develop strategies, make investment decisions and evaluate opportunities and threats. Freedonia research is designed to deliver unbiased views and reliable outlooks to assist clients in making the right decisions. Freedonia capitalizes on the resources of its proprietary in-house research team of experienced economists, professional analysts, industry researchers and editorial groups. Freedonia covers a diverse group of industries throughout the United States, the emerging China market, and other world markets. Industries analyzed by Freedonia include:

- Chemicals • Plastics • Life Sciences • Packaging • Building Materials • Security & Electronics • Industrial Components & Equipment • Automotive & Transportation Equipment • Household Goods • Energy/Power Equipment

[Click here to learn more about Freedonia](#)

**Freedonia Custom Research**

Freedonia Custom Research delivers the same high quality, thorough and unbiased assessment of an industry or market as an industry study. Since the research initiative is based upon a company's specific needs, companies harness Freedonia's research capabilities and resources to answer unique questions. When you leverage the results of a Freedonia Custom Research engagement, you are able to obtain important answers to specific questions and issues associated with: mergers and acquisitions, new product launches/development, geographic expansion, entry into new markets, strategic business planning, and investment and funding decisions.

Freedonia Custom Research is ideal for companies seeking to make a strategic difference in the status quo and focus on future business growth. Working side by side with clients, Freedonia's team is able to define a research project that is custom-tailored to answer specific questions and provide the basis from which a company can make informed business decisions.

[Click here to learn more about Custom Research](#)



[Click here for complete title list](#)



[Click here to visit freedoniagroup.com](http://www.freedoniagroup.com)